Human tissue-resident peritoneal macrophages reveal resistance towards oxidative cell stress induced by non-invasive physical plasma.

cold atmospheric plasma (CAP) human primary macrophages immune response non-invasive physical plasma (NIPP) peritoneal cancer peritoneal cavity plasma-activated media (PAM) plasma-treated solutions (PTS)

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 17 12 2023
accepted: 14 02 2024
medline: 20 3 2024
pubmed: 20 3 2024
entrez: 20 3 2024
Statut: epublish

Résumé

In the context of multimodal treatments for abdominal cancer, including procedures such as cytoreductive surgery and intraperitoneal chemotherapy, recurrence rates remain high, and long-term survival benefits are uncertain due to post-operative complications. Notably, treatment-limiting side effects often arise from an uncontrolled activation of the immune system, particularly peritoneally localized macrophages, leading to massive cytokine secretion and phenotype changes. Exploring alternatives, an increasing number of studies investigated the potential of plasma-activated liquids (PAL) for adjuvant peritoneal cancer treatment, aiming to mitigate side effects, preserve healthy tissue, and reduce cytotoxicity towards non-cancer cells. To assess the non-toxicity of PAL, we isolated primary human macrophages from the peritoneum and subjected them to PAL exposure. Employing an extensive methodological spectrum, including flow cytometry, Raman microspectroscopy, and DigiWest protein analysis, we observed a pronounced resistance of macrophages towards PAL. This resistance was characterized by an upregulation of proliferation and anti-oxidative pathways, countering PAL-derived oxidative stress-induced cell death. The observed cellular effects of PAL treatment on human tissue-resident peritoneal macrophages unveil a potential avenue for PAL-derived immunomodulatory effects within the human peritoneal cavity. Our findings contribute to understanding the intricate interplay between PAL and macrophages, shedding light on the promising prospects for PAL in the adjuvant treatment of peritoneal cancer.

Identifiants

pubmed: 38504975
doi: 10.3389/fimmu.2024.1357340
pmc: PMC10949891
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1357340

Informations de copyright

Copyright © 2024 Schultze-Rhonhof, Marzi, Carvajal Berrio, Holl, Braun, Schäfer-Ruoff, Andress, Bachmann, Templin, Brucker, Schenke-Layland and Weiss.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Laura Schultze-Rhonhof (L)

Department of Women's Health Tübingen, University of Tübingen, Tübingen, Germany.

Julia Marzi (J)

Institute of Biomedical Engineering, Department for Medical Technologies and Regenerative Medicine, University of Tübingen, Tübingen, Germany.
Natural and Medical Sciences Institute (NMI) at the University of Tübingen, Reutlingen, Germany.

Daniel Alejandro Carvajal Berrio (DA)

Institute of Biomedical Engineering, Department for Medical Technologies and Regenerative Medicine, University of Tübingen, Tübingen, Germany.

Myriam Holl (M)

Department of Women's Health Tübingen, University of Tübingen, Tübingen, Germany.

Theresa Braun (T)

Natural and Medical Sciences Institute (NMI) at the University of Tübingen, Reutlingen, Germany.
University Development, Research and Transfer, University of Konstanz, Konstanz, Germany.

Felix Schäfer-Ruoff (F)

Natural and Medical Sciences Institute (NMI) at the University of Tübingen, Reutlingen, Germany.

Jürgen Andress (J)

Department of Women's Health Tübingen, University of Tübingen, Tübingen, Germany.

Cornelia Bachmann (C)

Department of Women's Health Tübingen, University of Tübingen, Tübingen, Germany.

Markus Templin (M)

Natural and Medical Sciences Institute (NMI) at the University of Tübingen, Reutlingen, Germany.

Sara Y Brucker (SY)

Department of Women's Health Tübingen, University of Tübingen, Tübingen, Germany.

Katja Schenke-Layland (K)

Institute of Biomedical Engineering, Department for Medical Technologies and Regenerative Medicine, University of Tübingen, Tübingen, Germany.
Natural and Medical Sciences Institute (NMI) at the University of Tübingen, Reutlingen, Germany.

Martin Weiss (M)

Department of Women's Health Tübingen, University of Tübingen, Tübingen, Germany.
Natural and Medical Sciences Institute (NMI) at the University of Tübingen, Reutlingen, Germany.

Classifications MeSH